A2A

A2A Pharmaceuticals has designed new drug candidates for Leukemia and other cancers. A2A has also developed new antibiotics for gram negative bacteria infections.

A2As technology platform allows for optimization of efficacy with minimization of toxicity much faster and more precisely than competitors.

The track record for development of new drug candidates has been proven with work done for other pharmaceutical companies. Details are available on request.

COMPANY PEOPLE

Sridhar Vempati

Sridhar Vempati
Board Member & Co-Founder

Edward Painter

Edward Painter
CEO & Co-Founder

Matthew Welsch

Matthew Welsch
Consultant & Co-Founder

YOU MIGHT ALSO BE INTERESTED IN

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision.  Except as expressly stated by SOSV in writing, neither the SOSV website nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities.